



**HAL**  
open science

# Human innate lymphoid cell activation by adenoviruses is modified by host defense proteins and neutralizing antibodies

Océane Paris, Franck J.D. Mennechet, Eric J. Kremer

► **To cite this version:**

Océane Paris, Franck J.D. Mennechet, Eric J. Kremer. Human innate lymphoid cell activation by adenoviruses is modified by host defense proteins and neutralizing antibodies. *Frontiers in Immunology*, 2022, 13, pp.975910. 10.3389/fimmu.2022.975910 . hal-03982128

**HAL Id: hal-03982128**

**<https://hal.science/hal-03982128v1>**

Submitted on 26 Oct 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



## OPEN ACCESS

EDITED BY  
Jochen Mattner,  
University of Erlangen Nuremberg,  
Germany

REVIEWED BY  
Cathleen Carlin,  
Case Western Reserve University,  
United States  
Vijay Kumar,  
Louisiana State University,  
United States

\*CORRESPONDENCE  
E. J. Kremer  
eric.kremer@igmm.cnrs.fr

†These authors share senior authorship

‡PRESENT ADDRESS  
Franck J. D. Mennechet,  
Pathogenesis and Control of Chronic  
Infections, INSERM, Université de  
Montpellier, Montpellier, France

SPECIALTY SECTION  
This article was submitted to  
Vaccines and Molecular Therapeutics,  
a section of the journal  
Frontiers in Immunology

RECEIVED 22 June 2022  
ACCEPTED 09 September 2022  
PUBLISHED 05 October 2022

CITATION  
Paris O, Mennechet FJD and  
Kremer EJ (2022) Human innate  
lymphoid cell activation by  
adenoviruses is modified by host  
defense proteins and  
neutralizing antibodies.  
*Front. Immunol.* 13:975910.  
doi: 10.3389/fimmu.2022.975910

COPYRIGHT  
© 2022 Paris, Mennechet and Kremer.  
This is an open-access article  
distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Human innate lymphoid cell activation by adenoviruses is modified by host defense proteins and neutralizing antibodies

Océane Paris, Franck J. D. Mennechet<sup>†‡</sup> and E. J. Kremer<sup>\*†</sup>

Institut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France

Innate lymphoid cells (ILCs), the complements of diverse CD4 T helper cells, help maintain tissue homeostasis by providing a link between innate and adaptive immune responses. While pioneering studies over the last decade have advanced our understanding how ILCs influence adaptive immune responses to pathogens, far less is known about whether the adaptive immune response feeds back into an ILC response. In this study, we isolated ILCs from blood of healthy donors, fine-tuned culture conditions, and then directly challenged them with human adenoviruses (HAdVs), with HAdVs and host defense proteins (HDPs) or neutralizing antibodies (NABs), to mimic interactions in a host with pre-existing immunity. Additionally, we developed an *ex vivo* approach to identify how bystander ILCs respond to the uptake of HAdVs ± neutralizing antibodies by monocyte-derived dendritic cells. We show that ILCs take up HAdVs, which induces phenotypic maturation and cytokine secretion. Moreover, NABs and HDPs complexes modified the cytokine profile generated by ILCs, consistent with a feedback loop for host antiviral responses and potential to impact adenovirus-based vaccine efficacy.

## KEYWORDS

ILCs, adenoviruses, dendritic cells, innate immunity, vaccination, antiviral response

**Abbreviations:** APC, antigen-presenting cell; CAR, coxsackievirus and adenovirus receptor; CsCl, caesium chloride; CXCL10, C-X-C motif chemokine ligand 10; DC-SIGN, dendritic cell-specific ICAM 3-grabbing non-integrin; DGS2, desmoglein 2; FcγRs, Fc-gamma receptors; HAdVs, human adenoviruses; HDPs, host defense proteins; HNP-1, human neutrophil peptide-1; IFN, interferon; Ig, immunoglobulin; IL, interleukin; LPS, lipopolysaccharide; MFI, Mean fluorescent intensity; MHC-I/-II, major histocompatibility complex class I/II; moDCs, monocyte-derived dendritic cells; NABs, neutralizing antibodies; NK, natural killer (cell); NKT, natural killer T cell; PBMC, peripheral blood mononuclear cells; PRR, pattern recognition receptors; Th1 cells, T helper cells 1; Th2 cells, T helper cells 2; Th17/22 cells, T helper cells 17/22; TLR, Toll-like receptor; TNF, tumor-necrosis factor.

## Introduction

Innate lymphoid cells (ILCs) are functional kin to CD4 T helper (Th) cells. In contrast to Th cells, ILCs traffic through the lymphatic and vascular systems to preferentially reside in mucosal compartments where they help maintain a balance between anti-pathogen immunity and tolerance (1–3). Unlike T and B cells, ILCs do not express rearranged antigen-specific receptors (1). ILC interactions with neighboring cells are crucial events in the induction and development of immune responses (4, 5). In synergy with myeloid cells, ILCs respond to pathogens through the secretion of cytokines (6, 7). Like Th cells, ILCs can be functionally and phenotypically subdivided into subsets: ILC1 (which historically included cytotoxic NK cells), ILC2, and ILC3. NK cells appear to be counterparts of CD8<sup>+</sup> T cells, while ILC1, ILC2, ILC3 the counterparts of Th1, Th2, Th17/22 CD4<sup>+</sup> T cells, respectively (8, 9). LT $\alpha$  (lymphoid tissue-inducer) cells belong to the ILC3 subset and are involved in embryonic lymph node formation. Yet, ILC subsets are not static and show context-specific heterogeneity and plasticity, particularly as we age and during the development of antiviral responses (10, 11).

By the time we are adolescents, we have been infected with several human adenovirus (HAdV) types (12, 13). The archetypal robust and long-lived immune response against HAdVs is due, in part, to latent infections that persist for years and constantly re-stimulate the memory B- and T-cell responses (14–16). HAdV are nonenveloped particles with a linear double-stranded DNA genome of ~36 kilobase pairs. The more than 110 HAdV types are grouped into 7 species (A to G) (17). The variable tropism of HAdVs typically causes mild, self-limiting symptoms within 10 days post-infection (18, 19). Globally, HAdVs of species A and C mainly induce pathology in the respiratory, urinary, and gastrointestinal tracts. Species B HAdVs infections have the broadest tissue diversity and can cause disease in the respiratory, urinary, gastrointestinal and conjunctiva (17, 18). The species D HAdVs typically cause disease in the conjunctiva and gastrointestinal tracts, while those of species E affect the respiratory tract and conjunctiva. For HAdVs of species F and potentially G, symptoms are preferentially in the intestinal compartments (17).

In the era of COVID-19, HAdV-based vaccine efficacy and safety are of particular relevance (20–22). The roles ILCs play against HAdVs and HAdV-based vaccines are unknown. Moreover, whether the responses by ILCs are affected by pre-existing HAdV immunity has not been addressed. To fill this gap, we evaluated the interactions between human ILCs and three HAdV types that are used as vaccines: HAdV species C type 5 (-C5), species D type 26 (-D26), and species B type 35 (-B35) (5, 23, 24). These three HAdVs have different seroprevalence profiles and differ in the mechanism by which they are taken up by cells.

In this study, we initially tweaked a protocol for the culturing of ILCs from human blood. Then, we quantified ILC uptake of

HAdV-C5, -D26, and -B35 alone, or in complex with host defense proteins (HDPs), or neutralizing antibodies (NABs) (25–28). We characterized the levels of potential HAdV receptors, receptors for HDP- and NAB-complexed HAdVs, and relevant pattern recognition receptors (PRRs). Finally, as ILCs cooperate with neighboring antigen-presenting cells (6, 29, 30), we developed an *ex vivo* environment to mimic this interplay. We show that HAdVs complexed with HDPs or NABs induced differential cell surface levels of activation markers, and production of pro-inflammatory and antiviral cytokines with activities comparable to that of Th cells (31). As bystanders, the ILC response to monocyte-derived dendritic cells (moDCs) that are challenged with HAdVs  $\pm$  NABs, can be HAdV-type dependent. These data demonstrate that pre-existing B-cell immunity against HAdVs and HDPs directly impact ILC responses, which likely influence vaccine efficacy.

## Materials & methods

### Ethics

Human blood samples (fresh blood and buffy coat) were obtained from healthy adult anonymous donors at the regional blood bank (EFS, Montpellier, France). The study was approved by the Occitanie & Midi-Pyrénées EFS scientific board (EFS-OCPM: N°21PLER2019-0002). All donors provided written informed consent.

### Adenovirus vectors

The laboratory grade E1-deleted/E3<sup>+</sup> HAdV vector preps of HAdV-C5, HAdV-D26, HAdV-B35) are replication-defective in all primary cells. HAdV-C5 and HAdV-D26 vectors harbor an eGFP expression cassette (32) while HAdV-B35 harbors a GFP variant (YFP) cassette (33). The vectors were amplified in either human embryonic retinoblasts 911 (HER 911) or 293T E4-pIX cells and purified to >99% by two density gradients of CsCl (34, 35).

### Enrichment and selection of ILC

Peripheral blood mononuclear cells (PBMC) were isolated on a Ficoll-Histopaque<sup>®</sup> 1077 gradient (Sigma-Aldrich, Lyon, France). From PMBCs derived from fresh blood, innate lymphoid cells were enriched by negative immunomagnetic selection (EasySep Human Pan-ILC Enrichment Kit, cat# 17975, StemCell). The kit contained a cocktail of magnetic antibodies targeting the major cell lines of the immune system except ILCs. Enrichment was performed according to the manufacturer's instructions (36). Freshly enriched ILCs were

cultured in a complete medium consisting of RPMI supplemented with 10% human serum AB (sHAB), 10 ng/mL IL-7 (PeproTech<sup>®</sup>, Neuilly sur Seine, France), 1 mM sodium pyruvate (Gibco) and antibiotics (penicillin 100 I.U./mL and streptomycin 100 µg/mL). Different combinations of media were tested in the presence of IL-2, IL-12, and/or IL-7 at different concentrations (at 5, 10, 20, 30, or 90 ng/mL) or a commercial medium specific for NK cells (NK MACS Medium, cat# 130-114-429, MiltenyiBiotec) with lower efficacy. From the ~60 donors, we obtained, after enrichment, between  $2.7 \times 10^5$  and  $9 \times 10^5$  cells/donor, with an average of  $6.3 \times 10^5$  cells/donor. The percent yield of this enrichment protocol was from 0.02% to 0.7% with a mean of 0.18%. The predicted yield is 0.05 to 0.07% of mononuclear cells.

## Isolation and differentiation of monocytes-derived DCs

From PBMCs isolated from buffy coat, monocytes are purified by CD14<sup>+</sup> expression by positive immunomagnetic selection (MACS system, MiltenyiBiotec). CD14<sup>+</sup> cells were incubated for 6 days in the presence of 50 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) and 20 ng/ml interleukin-4 (IL-4) (PeproTech<sup>®</sup>, Neuilly sur Seine, France). The medium used for culture was RPMI, 10% foetal bovine serum (FBS) and penicillin 100 I.U./ml and streptomycin 100 µg/ml.

## Direct infection of ILCs with HAdV vectors

Approximately  $2.5 \times 10^4$  ILCs in 300 µl of complete medium were incubated in the presence of HAdV-C5-GFP, HAdV-D26-GFP or HAdV-B35-YFP at  $10^4$  physical particles (pp)/cell. The medium used for the infection step did not contain human serum. At 6 h post infection, human AB serum (10%) was added to HAdV alone and as NAb complexes. After 24 h of incubation, activation of ILCs was observed *via* level of the activation markers CD69 and CD161, as well as secretion of antiviral and immunomodulatory cytokines.

## Indirect stimulation of ILCs by moDCs

The first step consists in the stimulation of DCs by HAdVs alone or complexed with NAb. moDCs ( $5 \times 10^5$  cells in 400 µl of complete medium) were incubated with HAdV-C5-GFP, HAdV-D26-GFP or HAdV-B35-YFP ( $10^4$  physical particles (pp)/cell) for 6 h in complete RPMI DC medium. 6 h post-infection, the moDC supernatant was discarded and the cells washed with PBS and centrifuged at 1500 rpm for 5 min to

remove the HAdVs in the medium. The cells are then cultured in basal ILC medium (RPMI + 10% sHAB + P/S). Approximately 18 h after the medium change (24 h post-infection), the supernatant of activated moDCs was added to freshly isolated ILCs. After 24 h of incubation in the presence of supernatants from stimulated moDCs, ILC activation was characterized by the level of the activation marker CD69, as well as the secretion of antiviral and immunomodulatory cytokines.

## Formation of Ig - HAdV complexes

IVIg<sup>®</sup> or “Intravenous Immunoglobulin” (Baxter SAS, Guyancourt, France) was used as a control for IC formation and corresponds to a 95% IgG mix from healthy donor plasma (1,000 from 50,000 donors/batch). IVIg was used in patients with acquired immune deficiencies and autoimmune diseases. For the formation of Ig - HAdV complexes, HAdV-C5-GFP, HAdV-D26-GFP or HAdV-B35-YFP were incubated in the presence of decomplexed sera from a laboratory serum bank for 25 min at room temperature (34). The sera used may or may not have antibodies specific (in particular neutralizing antibodies, NAb) to the different HAdVs. Serum E (SE) had a very high NAb titre for HAdV-C5 (3500) but no NAb for HAdV-D26 or -B35. Serum A (SA) had a high titer of NAb for HAdV-D26 (2500) and low titres for HAdV-C5 (50) and -B35 (0). Serum 14 (S14) had titres of NAb for HAdV-B35 (2200), HAdV-C5 (2000) and HAdV-D26 (120). S14 was the only serum ( $n > 400$ ) for which we detected the presence of a high titre of HAdV-B35 NAb. After incubation, the newly formed Ig - HAdV complexes were cultured with the different cell types for 24 h. The ILCs (between  $2 \times 10^4$  cells and  $3 \times 10^4$  cells) or moDCs ( $5 \times 10^5$  cells) were incubated with  $10^4$  physical particles (pp)/cell of HAdVs ± IVIg.

## Formation of HDP - HAdV complexes

ILCs were incubated with  $10^4$  physical particles (pp)/cell of HAdVs (in 300 µl of complete medium). For the formation of HDP - HAdV complexes, HAdV-C5-GFP, HAdV-D26-GFP or HAdV-B35-YFP were incubated in the presence of HNP-1 (3.50 µg/mL) or lactoferrin (100 µg/mL) for 30 min at room temperature (26, 27). These concentrations were chosen to reproduce those found in an inflammatory environment of infected tissues. GFP levels and cytokines release were assessed after 24 h post-infection.

## Flow cytometry

CD127 FITC (cat# 560549, BD Pharmingen) or PE-CF594 (cat# 562397, BD Pharmingen) clone HIL-7R-M21, CD3 PerCP-

Cy5.5 (cat# 560835, BD Pharmingen) or CD3 APC (cat# 300412, BioLegend®) clone UCHT1, CRTH2 (CD294) PE clone BM16 (cat# 563665, BD Pharmingen), CD117 PE-Cy7 clone 104D2 (cat# 339217, BD Pharmingen) were used to identify the population of ILCs and exclude T cells (potential depletion contaminants). CD69 APC (cat# 555533, BD Pharmingen) or FITC (cat# 347823, BD Biosciences) and CD161 PE-Cy5 (cat# 551138, BD Pharmingen) were used to observe activation of ILCs after stimulation. The level of different cellular receptors involved in HAdVs infection was determined by using a panel of antibodies. Anti-CAR (cat# AF336, R&D systems) was used at 1/10th with Donkey anti-goat Alexa Fluor 488 secondary antibody (cat# A11055, Invitrogen), DC-SIGN (CD209) (cat# 561764, BD Pharmingen), Desmoglein 2 FITC (DSG2) clone AH12.2 (37) (cat# sc-80663FITC, Santa Cruz Biotechnology), CD46 APC (targets MCP protein) clone TLA-2-10 (cat# 352405, BioLegend®), CD49d APC (targets  $\alpha 4$  integrins) clone 9F10 (cat# 304307, BioLegend®), CD16 (targets Fc $\gamma$ RIII) clone 3G8 (cat# 302011, BioLegend®). Several Toll-Like receptors were explored: TLR2 FITC (CD282) clone TL2.1 (cat# 309706, BioLegend®), TLR3 PE (CD283) clone TLR-104 (cat# 315010, BioLegend®), TLR4 APC (CD284) (cat# 130-100-150), MiltenyiBiotec) and TLR9 APC clone eB72-1665 (cat# 560428, BD Pharmingen). The level of HLA-ABC FITC (cat# 557348, BD Pharmingen), HLA-DR FITC (cat# 555811, BD Pharmingen), CD80 FITC (cat# 557226, BD Pharmingen), CD83 FITC (cat# 556910, BD Pharmingen) and CD86 APC (cat# 555660, BD Pharmingen) was also analyzed for ILCs or moDC activation. GFP/YFP expression by infected ILCs or moDCs as well as other previously mentioned markers were assessed by flow cytometry (NovoCyte®). Antibody volumes were adapted to the number of cells for each cell type according to the manufacturer's instructions, and incubation was for 30 min at 4°C with gentle agitation. The cells were then washed twice (1800 rpm, 4°C, 5 min) and resuspended in 130  $\mu$ L of buffer (PBS + 10% fetal calf serum). 7-AAD (7-aminoactinomycin D, cat# 559925, BD Pharmingen) was added at 1/250<sup>th</sup> v/v, 10 min before reading to observe cell viability in each sample. All flow cytometry assays were obtained with the NovoCyte® flow cytometer and analyzed with NovoExpress software unless otherwise mentioned.

## Cytometric beads array

Supernatants were collected and cytokine secretion was measured using two panels of 13 cytokines (antiviral response and T helper cytokines) by using CBA, a multiplex cytokine quantification (LEGENDplex HU Anti-Virus Response Panel (13-plex) and LEGENDplex HU Th Cytokine Panel (13-plex) (cat# 740390 and cat# 740722, BioLegend) following the manufacturer's instructions. The concentration of each analyte will be quantified by flow cytometry *via* the signal

intensity and determined using known standard curve and the analysis software provided by the manufacturer (LEGENDplex). We selected the cytokines of interest from a secretion 2-fold higher than mock-treated for HAdVs and 2-fold higher than the HAdV alone condition for immune-complexes.

## Statistical analysis

Data were analyzed by GraphPad Prism 5 software and presented as the mean  $\pm$  SEM. The significance of the results was determined by using Student's paired *t*-test to make comparisons within each donor.

## Results

### ILC purity and stability

ILCs were obtained by negative immunomagnetic selection from anonymous blood bank donor PBMCs. To evaluate ILC recovery and purity, we used multi-parameter flow cytometry and a combination of markers including Lin<sup>-</sup>, CD127<sup>+</sup>, CRTH2<sup>+/-</sup> and CD117<sup>+/-</sup>. After enrichment, the cells were characterized according to their size and granularity. Approximately 50% of the cells had a lymphoid profile (Figure 1A). Within the lymphoid population, approximately 3% were CD3<sup>+</sup> (Figure 1B), and approximately 60% were CD3<sup>+</sup>/CD127<sup>+/-</sup> of which 22% were CD127<sup>high</sup> (Figure 1C). In this donor, 28% of the cells were ILC1 (CRTH2<sup>-</sup>/CD117<sup>-</sup>), 16% were ILC2 (CRTH2<sup>+</sup>/CD117<sup>+/-</sup>), and 56% were ILC3 (CRTH2<sup>+</sup>/CD117<sup>+</sup>) (Figure 1D). Cumulative data from >60 donors highlight the heterogeneity of ILCs in anonymous blood bank donors (Figure 1E). To assess the enrichment protocol, we identified ILCs pre- (Figures S1A, B) and post- (Figures S1C, D) negative selection from PBMCs. To identify non-ILCs in the enriched populations, we stained for NK, NKT, T, and B cells using CD16 and CD56, CD3, and CD19 and CD20, respectively. The percentage of contaminating NK and NKT cells was 0 - 5%, T cells 0 - 2%, and B cells 0.4 - 7% (Figure S1E).

Initially, we maintained ILCs in RPMI/human AB serum/IL-7, but we were limited to assaying ILC phenotype and functionality during the first 24 h post-enrichment. To attempt to prolong this window, we tested "NK medium", IL-2, and pyruvate. We found that the combination of RPMI/human AB serum (10%), IL-7 (10 ng/mL), and sodium pyruvate (1 mM) prolonged the phenotypic stability of the ILCs until ~48 h post-enrichment. Of note, IL-7 induces the internalization of CD127, the  $\alpha$  chain of the IL-7R. Therefore, from then on, we also gated on CD3<sup>+</sup>/CD127<sup>low</sup> cells, followed by CRTH2 and CD117 to identify the ILCs.






FIGURE 1

Enrichment and identification of ILCs from peripheral blood. Freshly isolated PBMCs were used for the negative selection of ILCs. (A) Population of cells post-negative selection. Of these, ~50% were lymphoid based on their size and granularity; (B) from the lymphoid population, we gated on the CD3<sup>+</sup> population and (C) in the CD3<sup>+</sup> population the majority of cells were CD127<sup>+</sup> (MFI for CD127<sup>+</sup> was 2269 vs. 668 for CD127<sup>-</sup>); (D) from the CD3<sup>+</sup> population we also screened for the presence of CRTH2 and CD117, which delimits the ILC populations; (E) cumulative data from 60 donors showed the range of percentage, the median, and the mean of each ILC subset.

## ILCs take up HAdV-C5, -D26 and -B35


Several cells are involved in the initial response to viral infections. ILCs could influence the immune response by responding to cells that take up viruses and/or by taking up the virus directly. To determine whether ILCs take up HAdVs, we incubated the cells with replication-defective ( $\Delta$ E1) HAdV-C5, -D26, or -B35 vectors encoding GFP variants. At 24 h post-challenge, we found an average uptake efficacy of 13.5% for HAdV-C5, 13% for -D26, and 17% for -B35 (Figure 2A).

We then broke these data down into the uptake of each HAdV type by each ILC subset. Globally, ILC2s appeared take up all three HAdVs more efficiently than ILC1 & 3s (Figures 2B-D). The uptake of each HAdV for a given subset of ILCs, suggested that ILC1 and ILC3s take up more HAdV-B35, followed by -C5 and -D26 (Figure S2). ILC2s more readily take up HAdV-C5 and -B35. Each ILC subset thus shows a modestly variable uptake profile depending on the HAdV type. The notable difference in efficacy between donors (e.g., 0 - 80% of cells for HAdV-B35) is not unique to ILCs: primary cultures of monocytes and moDCs also show high interdonor variability (34, 38, 39). Together, these data suggest that all ILC subsets could be involved in the detection of HAdV capsids.

## ILCs express receptors used by HAdV-C5, -D26 and -B35

We then screened for the receptors by which HAdVs could be taken up. CAR (coxsackievirus and adenovirus receptor) is a single-pass transmembrane cell adhesion molecule expressed by many cell types and is a primary attachment molecule for numerous HAdV types (40, 41). We were unable to unequivocally detect CAR on ILCs (Figure 3A). These data are consistent with RNAseq results showing 1.5 nTPM (normalized transcripts per million) of CXADR mRNA ([www.proteinatlas.org](http://www.proteinatlas.org)), Ercolano et al. (Table S1) (42) and Mazzurana et al. (43). DC-SIGN (or CD209) (44, 45), a C-type lectin receptor present on the surface of macrophages, and conventional and plasmacytoid DCs, is a low affinity/high avidity receptor for some HAdV types (46). Similar to CAR, we were unable to unequivocally detect DC-SIGN on ILCs (Figure 3B), which is consistent with the transcript level (0.2 nTPM).

MHC class I (HLA-ABC) molecules have also been reported to act as a receptors for HAdV-C5 (47), and are high on ILCs (Figure 3C) (2946 nTPM). Of note, the diverse haplotypes could be an explanation for the inter-donor variability in HAdV type uptake efficacy. CD46, a type I transmembrane protein that is part of the complement system, is used by some cells to take up



**FIGURE 2**

Evaluation of the capacity of ILCs to take up HAdV-C5, -D26 and -B35. HAdV vector-mediated GFP expression in total ILCs and in ILC subsets was quantified 24 h post-incubation (n = 16). The panels on the left (colour-coded to facilitate ILC subset identification) are representative data from a single donor, while panels on the right are cumulative data. **(A)** Result from one donor after HAdV-D26 uptake and mean percentages  $\pm$  SEM of total ILCs expressing GFP after infection; **(B–D)** For each HAdV type, result from one donor after uptake by ILC1, ILC2, or ILC3 and mean percentages  $\pm$  SEM of the ILC subsets expressing GFP after infection with **(B)** HAdV-C5, **(C)** HAdV-D26, or **(D)** HAdV-B35 (right panel). Statistical analyses were performed using paired Student's *t* test by comparing uninfected cells and cells challenged with the HAdVs (ns, *p* > 0.05, \* *p*  $\leq$  0.05, \*\* *p*  $\leq$  0.01, \*\*\* *p*  $\leq$  0.001).




FIGURE 3

Expression of candidate HAΔV receptors by human peripheral blood ILCs. Levels of (A) CAR, (B) DC-SIGN, (C) HLA-ABC (MHC-I), (D) CD46, and (E) CD49d, in freshly isolated total ILCs, ILC1, ILC2 and ILC3. Cell populations were normalised to 100%. Data are representative of 2 - 4 donors.



HAdV-D26 and -B35 (48, 49). CD46 was readily detected on essentially all ILCs (Figure 3D) and also by scRNAseq (263 nTPM).

We also quantified the level of CD49d (integrin  $\alpha_4$ ), which is a low affinity auxiliary receptor for some HAdVs, including HAdV-C5 (50). CD49d was readily detected on >90% of the ILCs (189 nTPM) (Figure 3E, gMFI for levels can be found in Figures S3A, B). Finally, desmoglein 2 (DSG2), another cell adhesion molecule, is used by some cells to take up some species B and D HAdVs (51). DSG2 levels were undetectable by immune-based assays. scRNAseq results varied between 0 and 42 nTPM (average 11 nTPM).

Together, these data (summary in Table 1 and Figure S3C) shed light on the potential pathways by which ILCs take up HAdV-C5, -D26 and -B35.

## ILC phenotypic activation and cytokine secretion after HAdV uptake

ILCs orient adaptive immune responses through the production of cytokines. We therefore examined cytokines involved in antiviral, and initiation or orientation of adaptive immunity following challenge with HAdVs. Due to the limited number of cells/donors, we screened total ILCs. Compared to mock-treated cells, we found an antiviral response consisting of IL-1 $\beta$ , TNF, IFN- $\lambda_1$ , and IFN- $\gamma$  (<100 pg/ml); IL-8 and INF- $\beta$  (100 - 200 pg/ml), and IFN- $\lambda_{2/3}$  (>200 pg/ml), and a Th response consisting of IL-5, IL-6, IL-9, IFN- $\gamma$  and IL-21 (<100 pg/ml) (Figure 4A). TNF and IFN- $\gamma$ , which have antiviral and Th functions, were comparable in each panel.

We then characterized the HAdV-induced phenotypic activation. Using ILCs immediately post-enrichment, we quantified the cell surface levels of CD69, an early activation marker expressed by lymphoid cells; CD161, whose expression

increases during inflammation (mainly on NK cells); the costimulatory molecules CD80 and CD86; and MHC II molecules. We found that <20% of ILCs had baseline levels of CD69 (Figure 4B), while approximately 43% of the cells were CD161<sup>+</sup> (Figure 4C). We were unable to unequivocally detect CD80, CD86, and HLA-DR (Figure S4), consistent with RNAseq data (42, 43). LPS challenge modestly increased the percentage of CD69<sup>+</sup> ILCs (35%), with the greatest impact on ILC3s (40%). After incubation with HAdV-C5, -D26, or -B35, we observed a selective increase in CD69 levels in ILC2s (Figure 4D). Therefore, ILCs challenged with HAdVs secreted cytokines with antiviral and Th activities and modestly increased a phenotypic marker of activation.


## Impact of pre-existing immunity against HAdVs on the ILC response

HAdV-based vaccines are being used to limit COVID-19 severity and are being trialled for other emerging pathogens (52). The use of HAdV-C5-based vaccines has shown that, while pre-existing humoral immunity typically reduces vaccine efficacy, vaccine-induced inflammation is not significantly affected (52). Secondly, a long-term issue will be the ability to reuse HAdV-based vaccines after their nearly global deployment against SARS-CoV-2, which should induce widespread HAdV type-specific immunity. Depending on the cell type and the presence of Fc $\gamma$ Rs, anti-HAdV antibodies can either inhibit or increase HAdV uptake (53–56). For example, most sera containing HAdV NAb are characterized by their ability to inhibit infection of epithelial cells. Yet, these same sera can increase HAdV uptake by professional APCs *via* Fc $\gamma$ RIII (CD16) (34, 57). Fc $\gamma$ R-mediated uptake also increases the phenotypic and functional maturation of moDCs and plasmacytoid DCs (25, 34, 39, 57). By contrast, Ab that neutralize HAdV-B35

TABLE 1 Summary of the expression of (A) candidate receptors for HAdVs and (B) receptors/markers with a role in immunity by human peripheral blood ILCs.

A										
	CAR	DC-SIGN	CD46	CD49d	DSG2	CD16				
ILC1	≤ 5% (n.s)	< 2% (n.s)	≥ 85%	≥ 78%	< 5% (n.s)	≤ 27% (n.s)				
ILC2	≤ 15% (n.s)	< 10% (n.s)	≥ 95%	> 60%	< 5% (n.s)	< 10% (n.s)				
ILC3	≤ 5% (n.s)	≤ 1% (n.s)	≥ 95%	> 90%	< 5% (n.s)	< 12% (n.s)				
B										
	TLR2	TLR3	TLR4	TLR9	MHC-I	MHC-II	CD80	CD86	CD69	CD161
ILC1	< 10% (n.s)	~45%	< 10%	(n.s)	> 20% (n.s)	< 20%	≤ 6% (n.s)	< 12% (n.s)	< 20%	< 50%
ILC2	< 10% (n.s)	~45%	< 25%	< 10%	> 95%	< 20%	≤ 6% (n.s)	< 12% (n.s)	< 20%	< 50%
ILC3	< 10% (n.s)	~45%	< 10%	(n.s)	> 95%	< 20%	≤ 6% (n.s)	< 12% (n.s)	< 20%	< 50%

n.s, not significant.



**FIGURE 4** Cytokine release and phenotypic profile of ILCs after HAdV uptake. **(A)** Cytokines belonging to an antiviral panel or a Th screen were quantified from the supernatant of HAdV-challenged ILCs by CBA (n = 5). Cytokine levels are denoted by the colour code and the results were analyzed with the LegendPlex™ software. Only the cytokines whose levels were at least 2-fold higher than that of the controls are shown. Baseline levels of **(B)** CD69 and **(C)** CD161 in freshly isolated total ILCs, ILC1, ILC2 and ILC3 (n > 26). Cell populations were normalised to 100% (n ≥ 5); **(D)** CD69 levels ± SEM in ILC1, ILC2 and ILC3 post challenge with HAdV-C5, -D26, or B35 (n = 15). \* represents a individual donor symbol.

infection of epithelial cells also decreased transgene expression in DCs (58).

Therefore, we asked whether NAb impact HAdV uptake by ILCs. To form the complexes, we used selected sera that neutralized HAdV-C5, -D26 and -B35 infection of epithelial cells (58). Following the challenge of ILCs with the HAdV-NAb complexes, we observed a modest increase in cells expressing the transgene when type-specific NAb were complexed HAdV-C5 and -D26 compared to HAdVs alone (Figure 5A). Consistent

with previous data, we found that serum that contained HAdV-B35 NAb tended to decrease the percentage of GFP+ ILCs. When broken down into ILC subsets, we observed a modest increase in GFP levels in the presence of NAb-complexed HAdVs for ILC1 and 2 (Figures 5B, C, E). However, for ILC3 challenged with HAdV-C5-NAb complexes, we observed a modest decrease in the percentage of GFP+ ILCs (Figures 5D, E).

If one compares the subsets, ILC2s (34%) and ILC1s (29%) are more permissive to HAdV-D26-NAb complexes than

ILC3s (19%). In addition, ILC1s (15%) appeared to take up more particles/cell (higher gMFI) than ILC3s (7.5%) after HAdV-B35-NAb complex challenge (Figure S5). We therefore quantified the level of FcγRIII, and found lower

levels on the surface of ILC1 and 2s versus ILC3s (Figure 5F). Globally, ILC2 were the most permissive, while ILC3s appeared the least capable of taking up HAdV complexed with NAb (summarized in Figure S5).




FIGURE 5

ILC uptake of HAdV-NAb complexes and impact on FcγRIII levels. GFP levels in total ILCs, ILC1, ILC2 and ILC3 24 h post-incubation with each HAdV ± NAb. Sera “E”, “A”, and “14” inhibit HAdV-C5, -D26, or -B35, respectively, uptake by epithelial cells. (A) Mean percentages ± SEM of total ILCs expressing GFP after HAdV ± NAb challenge. (B-D) Mean percentages ± SEM of ILC1, ILC2, and ILC3 expressing GFP after challenge ± NAb. (E) Summary of the impact of NAb on ILC uptake of HAdV-C5, -D26 and -B35. (F) Levels of FcγRIII in freshly isolated total ILCs, ILC1, ILC2, and ILC3. Statistical analyses were performed using paired Student’s *t* test by comparing uninfected cells and cells challenged with the HAdVs (ns =  $p > 0.05$ ), \*  $p \leq 0.05$  ( $n \geq 5$ ).

We then characterized phenotypic activation induced by HAdV-NABs. In contrast to the HAdVs alone, we found a decrease in CD69 levels following a challenge by NAb-complexed HAdVs (Figure 6A). Moreover, each ILC subset tended to have less CD69 on the surface following a challenge by NAb-complexed HAdVs (Figure 6B). Together, these data suggest that pre-existing B cell immunity can modestly and differentially impact the ILC response to HAdVs, likely based on molecules used to take up HAdVs or HAdV-NAB complexes.

## Pattern recognition receptors


The initial 24 h can be critical when responding to pathogens or vaccines. It was noteworthy that ILC uptake of HAdVs induced IL-8 secretion, which will lead to the recruitment of monocytes and neutrophils (Figure 4A). The cytoplasmic content of neutrophils can be as much as 20% HDPs, which are effector molecules of the innate immune system. Moreover, we previously showed that human neutrophil protein-1 (HNP-1) and lactoferrin bind to HAdV-C5, -D26 and -B35 and, by acting as bridges *via* TLR4, increase HAdV uptake by DCs (25–28).

As phenotypic and functional activation of innate immunity are initiated by the engagement of PRRs, we screened for the presence of PRRs and markers that serve could as inducers of activation. Despite differences between donors, we found that the majority of the CD3<sup>+</sup>/CD127<sup>+</sup> cells contain relatively low levels of TLR2 (<5%), TLR4 (<7%) and TLR9 (<6%), but

significant intracellular levels of TLR3 (Figures 7A, B and S6). Importantly though, LPS, a quintessential TLR4 ligand, induces ILCs to secrete pro-inflammatory cytokines, suggesting that while TLR4 levels are not high, TLR4-like signaling can be triggered (Figure S6). We therefore asked if HNP-1 or lactoferrin influences ILC uptake of HAdVs. ILCs were incubated with HAdV-HNP-1 or HAdV-lactoferrin complexes and uptake was quantified by GFP expression. In contrast to DCs, we found that the HDP-HAdV complexes either had no effect or were less readily taken up by ILCs (Figures 7C, S7). We then quantified ILC cytokine secretion induced by the HAdV-HDP complexes. When focusing on IL-8 levels, we again found that the response to HAdV-C5 and -D26 separated from that of -B35: when HAdV-C5 and -D26 were incubated with HNP-1 or lactoferrin, ILCs secreted higher levels of IL-8, while HAdV-B35 plus HNP-1 or lactoferrin decreased IL-8 levels compared to the HAdV alone. (Figure 7D). The levels of other cytokines did not change notably with respect to the addition of HNP-1 or lactoferrin (Figure 7E).

## Phenotypic maturation and cytokine secretion of bystander ILCs

Because ILCs respond to local cues, we tried to generate an *ex vivo* environment to characterize their response to DCs challenged with HAdVs. In this approach, HAdVs ± NABs were incubated with moDCs, the moDCs were rinsed to






FIGURE 7

PRR expression and impact of HDPs on uptake and cytokine profile. The levels of (A) TLR3 by ILCs; and (B) TLR9 by total ILCs, ILC1, ILC2, and ILC3. Cell populations were normalised to 100%. Results are representative of 2 - 5 donors. (C) ILC uptake of HADVs complexed with HNP-1 or lactoferrin: GFP expression by ILCs was quantified 24 h post-challenge with each HADV ± HDP (HNP-1 or lactoferrin) for total ILCs (n = 4). (D) Cytokines release in the presence of HNP-1 or lactoferrin: cytokines belonging to an antiviral panel and a Th cytokine panel in the supernatant of HADV-infected ILCs was quantified using CBA (n = 4). Cytokine levels are denoted by the colour code and the results were analyzed with the LegendPlex™ software. Only the cytokines whose secretion level was at least 2-fold higher than that of the controls are presented. (E) IL-8 secretion was assessed 24 h post-challenge with each HADV ± HDP for total ILCs (n = 4). Statistical analyses were performed using paired Student's *t* test by comparing uninfected cells and cells challenged with the HADVs.

remove HADVs and NAbs, fresh medium was added, and this latter media was collected 18 h later and added to ILCs. Initially, we observed a 2-3-fold increase in CD69 levels in ILCs due to moDC supernatant (Figures 8A-C). The supernatant from LPS-

challenged DCs induced a modest increase in CD69 levels on ILCs, with the greatest impact on ILC3s. When comparing the indirect impact of HADV-C5, D26 and -B35, it is noteworthy that HADV-C5, the “gold standard” for HADV immunogenicity,


had the lowest impact on ILC1 and ILC2 phenotypic maturation. When assaying the supernatant from DCs challenged with HAdV-C5-NAb complexes, the number of CD69<sup>+</sup> ILC1 and 2s increased compared with HAdV-C5 alone. In the case of HAdV-D26-NAb complexes, CD69<sup>+</sup> levels either decreased (ILC2s, Figure 8B) or did not change (ILC1 and 3s, Figures 8A, C). Finally, finding serum that neutralizes HAdV-B35 is challenging: in the greater than 400 sera analyzed, we found 1 that inhibited HAdV-B35 infection of epithelial cells. However, due to limited quantities of serum, we were able to perform only 2 assays and therefore the interpretation of these data should take this into account. We found that in contrast to ILC1 and 2s, the ILC3 response to HAdV-B35-NAb complexes was notably higher (Figure 8C).

Using the bystander challenge model, we also explored the cytokines secreted by ILCs. As above, we found a mixed antiviral and Th response consisting of TNF, IFN- $\lambda_1$ , IL-6, CXCL10, and IL-8 (Figures 8D, S8). We concluded that bystander ILCs respond to DCs challenged with HAdVs  $\pm$  NAb and that this

response could vary in hosts who have pre-existing HAdV immunity.

## Discussion

Initially, we tested selected culture conditions to prolong the ILC phenotype found immediately post-purification. The challenge was to increase viability, while maintaining their ability to respond to challenges. In murine ILCs, IL-2, -7 and -12 are involved in survival and stability (59, 60). As IL-2 and IL-12 can impact the activity and sensitivity of human peripheral blood ILCs, we opted for IL-7, which is involved in the development and maturation of ILCs (61). In addition, the IL-7 receptor is CD127, a marker also used for the identification and selection of ILCs that is internalized in the presence of its ligand. Therefore, we selected a concentration of IL-7 to maintain the development of the cell population, while minimizing the internalization of





CD127. Finally, based on the metabolic networks that may govern ILC functions (62), in particular the increase in glycolysis, we hypothesized that increased pyruvate levels could prolong the ILC phenotype/function.

The multitasking roles that ILCs play during virus infection have been addressed in numerous situations (10). However, how pre-existing immunity against a virus, or virus-based vaccines, impacts an ILC response is poorly understood. In this study, we addressed how human ILCs, isolated from peripheral blood, respond to three human adenovirus types, from three species. In addition to the binary ILCs - HAdVs interactions, we investigated how the presence of NAbS and HDPs impacted the ILC response. Because ILC responses are influenced by their environment, we also created an assay to explore how HAdV uptake by antigen-presenting cells (e.g., DCs) influences ILC physiology. We show that *i*) the three ILC subsets can be infected by three HAdV types with variable efficacy; *ii*) depending on the HAdV type, NAbS can either increase or decrease uptake by ILCs; *iii*) ILCs can respond differentially to HAdVs alone or those bound by NAbS or HDPs; and *iv*) the phenotypic profile of, and cytokine release by, ILCs is also responsive to indirect stimulation by HAdV-challenged DCs. Our results demonstrate that the adaptive immune response feeds back into ILC function, which likely impacts HAdV-based vaccine efficacy.

When working with primary ILCs from multiple donors, the heterogeneity of the response is typically considerable. ILC levels in peripheral blood vary with age (up to 7-fold less in older adults compared to children), sex (less abundant in males), and whether responding to a viral infection (11). While our approach inherently creates challenges for broad interpretations, it nonetheless represents a sampling of the diverse human responses. An important issue to take into account is that we poorly understand how modest changes in the level of cell surface markers of activation, or cytokines secreted impact immune responses. Moreover, using ILCs from peripheral blood creates additional challenges. Initially, ILCs seed tissues early in the life. During adolescence, it appears that ILCs are replaced by tissue-resident T cells that undertake a role in immune surveillance (63, 64).

Like many respiratory pathogens, the initial HAdV-associated illness is typically a childhood event. HAdVs also cause disease in multiple tissues (eyes, respiratory and gastrointestinal tracts). The divergent response from tissue resident ILCs should help drive a robust and complex adaptive response to HAdVs. Moreover, in spite of robust anti-HAdV B- and T-cell responses in most adults, HAdVs can maintain long-term persistence (65). Whether the initial immune response, which likely involves ILCs, plays a role in latency or HAdV-based vaccine efficacy is unknown. Given ILC ability of self-renewal in tissue, it is possible that antigen-specific memory ILCs (66) will, someday, be identified.

Are childhood infections and responses to HAdV-based vaccines in adolescents or adults linked? An argument could be put forward that there is an incompatibility in locales – HAdV-based vaccines are, for the moment, delivered subdermal/intramuscularly, whereas HAdV infections, to the best of our knowledge, rarely occur there. Importantly though, ILCs do not have an obligate tissue-specific residency (10). ILC homing receptors suggest a context-dependent capacity of some subsets for inter-organ trafficking. In addition, in spite of the T-cell-like functional (8, 9), all ILC subsets took up HAdVs. We also observed variations in the level of potential HAdV receptors, which was consistent with uptake efficacy. These data suggest that ILCs can play a direct role in the initiation of the immune response. Moreover, these data also suggest that functional diversification into Th1, Th2 and Th17/22-like T cells plays a minor role during initial interactions with HAdVs. However, an analysis that we were technically unable to perform was to identify which ILCs secrete which cytokines. ILC uptake of HAdVs generally increased CD69 levels, while the addition of NAbS tended to decrease CD69 level. These observations do not dovetail well with the uptake profile where NAb-HAdV-C5 and -D26 complexes increased the expression of the transgene by ILCs. The challenge of bystander ILCs *via* infected moDCs also induced a global increase in CD69 levels. The presence of NAbS during moDC challenge increased CD69 levels by ILCs compared to HAdVs alone for -C5 and -B35 and to a decrease for -D26. These patterns underscore the complex role of ILCs after HAdV interactions, particularly in the presence of NAbS.

Yet, as expected, the ILC antiviral response included type I (IFN- $\beta$ ), II (IFN- $\gamma$ ) and III (IFN- $\lambda$ ) IFNs. The levels of TNF, IL-6 and IL-21 were moderate and potentially have a synergistic action rather than individual. TNF is a pro-inflammatory cytokine with a more general role in the induction and stimulation of surrounding immune cells. IL-6 contributes to host defense by stimulating acute phase responses, hematopoiesis and immune responses (67), but has fundamentally different activities depending on its cytokine partners (68). IL-21 is a pro-inflammatory, notably inducing IL-8 secretion, maintaining CD8 T cell function and enhancing antigen presentation by phagocytes (69, 70). In the context of potential HAdV uptake during the first 24 h, the recruitment of HDP-loaded neutrophils could have a significant impact if HNP-1-mediated HAdV uptake influences ILCs directly or indirectly (increasing uptake by local phagocytes) (71). Unexpectedly, the bystander ILC response induced a cytokine profile similar to that of direct HAdV uptake, at a higher level. We also note the secretion of CXCL10, a pleiotropic molecule that can promote the chemotactic activity of CXCR3<sup>+</sup> cells, induces apoptosis, and is associated with antiviral responses (72–76).

From these data, we concluded that the ILC response to HAdVs varies in multiple situations (Figure S9). Moreover, the

vast and intriguing inter-donor variability leaves little room for a simple, text-book style conclusion. Identifying biomarkers for ILC status and differences could enable better exploitation and understanding of their responses to viruses and virus-based vaccines. Some of the future challenges to address during the use of HAdV-based vaccines is whether tissue-resident ILCs maintain their subtype-specific phenotype. This is unlikely to be a straightforward assay, as we will need to take into account health status, immunological history, age, and sex. Moreover, the dynamic environment at the site of vaccine injection during the initial 48 h is difficult to mimic *ex vivo*. While pre-existing B-cell immunity had a modest effect on uptake by ILCs from peripheral blood, it is unclear if this can be extended to tissue resident ILCs. Another issue is whether ILCs are efficiently recruited from the blood or from other compartments in a host with pre-existing immunity. Moreover, we expected to find a more prominent role for ILC2s in the context of HAdV-based vaccines. Further assays will be needed to determine whether skin ILCs behave differently. A greater understanding of ILC – adenovirus interactions (in particular the cytokine profile of the subsets) is needed to determine whether ILC-targeted or de-targeted Ad-based vaccines can improve efficacy or the duration of protection.

## Data availability statement

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding author.

## Ethics statement

The studies involving human participants were reviewed and approved by EFS-OCPM: N°21PLER2019-0002. The patients/participants provided their written informed consent to participate in this study.

## Author contributions

Study design & conception: OP, FM and EK. project direction: FM and EK. Performed experiments, OP. and analyzed data: OP, FM and EK. Wrote the manuscript: OP & EK. Secured funding: FM and EJK. All authors contributed to the article and approved the submitted version.

## Funding

This study was supported by Ph.D. fellowship from the French Minister of Education (OP), the Institut de Génétique Moléculaire de Montpellier (IGMM) (EJK), the French national

center of scientific research (CNRS) (EJK) and the Pierre Fabre foundation (FM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Acknowledgments

We thank the imaging facility MRI (ANR-10-INBS-04), Etablissement Français du Sang, and the Plateforme de Vectorologie de Montpellier (PVM, IGMM). We thank Coraline Chéneau for vector preparation, and Anne-Sophie Bedin (UMR 1058, Inserm, Montpellier) for help with the labelling of ILCs. We thank EKL members for constructive comments. We are grateful to Eric Weaver and Andre Lieber for providing HAdV-D26 and HAdV-B35, respectively.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2022.975910/full#supplementary-material>

### SUPPLEMENTARY TABLE 1

Summary of candidate receptors based on scRNAseq analyses of human ILCs. ScRNAseq data of candidate receptors by ILCs extracted from the results matrix published by Ercolano et al. Raw sequencing data were normalized to 1 million transcripts (nTPM).

### SUPPLEMENTARY FIGURE 1

Enrichment, stability, and characteristic of human ILCs. ILCs were identified pre- and post- negative selection from PBMCs. (A) Using total PBMCs, we gated on the CD45<sup>+</sup> population, and within this population, we gated on the Lin<sup>-</sup> and CD127<sup>+</sup> population. (B) Within the CD127<sup>+</sup> population, we gated on CRTH2 and CD161 high (ILC2) and low populations (not ILC2). In the not ILC2 population, we screened for CD117 to distinguish between ILC1 and ILC3 (NKp44<sup>-</sup> and NKp44<sup>+</sup>) populations. ILC1 are identified in fuchsia, ILC2 in light blue and ILC3 in green and dark blue. (C) Characterization of ILC populations post-

negative selection: 85% of the by CD45<sup>+</sup> cells were Lin<sup>-</sup>. Within the Lin<sup>-</sup> population, >90% were CD127<sup>+</sup>. **(D)** Within the CD127<sup>+</sup> population 62% were CRTH2 and CD161 high (ILC2). Within the CRTH2 and CD161 low population (not-ILC2s), ~86% were ILC3s (NKp44<sup>-</sup> and NKp44<sup>+</sup>) and 14% were ILC1s. **(E)** Quantification of the NK, NKT, T and B cells after negative selection. Lymphoid cells and granulocytes were screened with CD45. In parallel monocytes and macrophages were gated by CD4<sup>+</sup> and CD14<sup>+</sup>. From lymphoid cells, we screened for the presence of CD3 (LyT) and CD19 (LyB), then for CD20 and CD19. Finally, we gated on CD56 and CD16 within lymphoid cells (NKT cells) and within lymphoid cells LyT excluded (NK cells). Summary of NK and NKT cells, LyT and LyB present post-enrichment. Results were obtained with the Navios flow cytometer (Beckman Coulter) and are representative of 3 donors.

#### SUPPLEMENTARY FIGURE 2

Infection efficiency of human ILCs with HAdV-C5, -D26 and -B35. GFP expression by ILCs was measured 24 h post-challenge with each HAdV vector for ILC1, ILC2 and ILC3 (n = 16). The mean percentages of cells expressing GFP after infection  $\pm$  SEM were **(A)** for ILC1: HAdV-C5: 18%/HAdV-D26: 12.5%/HAdV-B35: 23%; **(B)** for ILC2: HAdV-C5: 25%/HAdV-D26: 19%/HAdV-B35: 24%; **(C)** for ILC3: HAdV-C5: 14%/HAdV-D26: 14%/HAdV-B35: 16%. Statistics were performed by paired Student's t test by comparison with uninfected cells and between different HAdV (ns, p > 0.05, \* p  $\leq$  0.05, \*\* p  $\leq$  0.01, \*\*\* p  $\leq$  0.001). We noted a significant difference between HAdV-C5 and -D26 and then HAdV-D26 and -B35 for ILC2 (\* p  $\leq$  0.05), but a non-significant difference between the HAdVs tested for ILC1 and ILC3.

#### SUPPLEMENTARY FIGURE 3

Median Fluorescence Intensity (MFI) and gMFI of the expression of candidate receptors for HAdVs by human peripheral blood ILCs. MFI and gMFI for **(A)** HLA-ABC<sup>+/+</sup>, **(B)** CD46<sup>+/+</sup> and CD49d<sup>+/+</sup> cells for each ILC subset and the fold changes were shown for a representative donor. The MFI of 10 (red) correspond to the minimum of fluorescent measured. **(C)** Mean expression  $\pm$  SEM of candidate receptors for HAdVs (upper panel) and for molecules involved in the immune response (lower panel) (n  $\geq$  2).

#### SUPPLEMENTARY FIGURE 4

Activation and co-stimulatory molecule levels in human ILCs. Levels of **(A)** CD80, **(B)** CD86 and **(C)** MHC-II (HLA-DR) in freshly isolated total ILCs, ILC1, ILC2 and ILC3. Cell populations were normalized to 100%. Results were obtained with the NovoCyte<sup>®</sup> flow cytometer and analyzed with

NovoExpress software. Due to high donor variation, the results presented represent only one donor among the 3 tested (CD80 and CD86).

#### SUPPLEMENTARY FIGURE 5

ILC uptake of HAdVs in the presence of NAbs. **(A-C)** GFP expression by ILC1, ILC2 and ILC3 was measured 24 h post-challenge with **(A)** HAdV-C5-SE, **(B)** -D26-SA, or **(C)** -B35-S14 (n  $\geq$  5). Sera E, A, and 14 have NAbs against HAdV-C5, -D26, and -B35, respectively. **(D)** MFI and gMFI for GFP<sup>+</sup> and GFP<sup>-</sup> cells for each ILC subset and the fold changes for the mean of 2 representative donors were presented. Statistical analyses by paired Student's t test were performed by comparison between ILC subsets for each Ig-HAdVs complexes (ns, p > 0.05, \* p  $\leq$  0.05).

#### SUPPLEMENTARY FIGURE 6

Level of Toll-like receptors by human ILCs directly isolated from peripheral blood. **(A)** TLR2 levels by total ILCs, ILC1, ILC2, and ILC3; **(B)** TLR4 levels by total ILCs, ILC1, ILC2, and ILC3. Cell populations were normalized to 100%. Results are representative of 2-5 donors. **(C)** Cytokine profile secreted by ILCs after incubation with (LPS) or without (ILCs) LPS for T helper cytokines panels using CBA. Data are representative of one donor.

#### SUPPLEMENTARY FIGURE 7

Identification of ILCs and HAdVs uptake in the presence of HDP. **(A-C)** ILCs are among CD3<sup>+</sup>/CD127<sup>+</sup> lymphoid cells; **(D)** GFP levels by ILCs were measured 24 h post-challenge with each HAdV  $\pm$  HDP (HNP-1 or lactoferrin) for total ILCs.

#### SUPPLEMENTARY FIGURE 8

Bystander effect on ILC maturation: IL-8 levels. IL-8 secretion by human total ILCs was assessed 24 h after indirect challenge by moDCs for each HAdV  $\pm$  NAbs (n = 3).

#### SUPPLEMENTARY FIGURE 9

Summary tables of infection and activation/stimulation of ILCs by HAdVs or infected moDCs in the presence or absence of Nabs. **(A)** Infection capacity of ILCs by HAdVs. **(B)** Level of the CD69 marker by ILCs. **(C)** Secretion of cytokines by ILCs. **(D)** GFP and CD86 levels by DCs after HAdVs challenge. **(E)** CD69 level by ILCs after indirect challenge by moDCs. **(F)** Secretion of cytokines by ILC after indirect challenge by moDCs. Only cytokines with a secretion level at least 2-fold higher than controls were shown. *IC for Ig - HAdVs complexes.*

## References

- Spits H, Artis D, Colonna M, Dieffenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells—a proposal for uniform nomenclature. *Nat Rev Immunol* (2013) 13:145–9. doi: 10.1038/nri3365
- Peters CP, Mjösberg JM, Bernink JH, Spits H. Innate lymphoid cells in inflammatory bowel diseases. *Immunol Lett* (2016) 172:124–31. doi: 10.1016/j.imlet.2015.10.004
- Kim CH, Hashimoto-Hill S, Kim M. Migration and tissue tropism of innate lymphoid cells. *Trends Immunol* (2016) 37:68–79. doi: 10.1016/j.it.2015.11.003
- Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK, Doering TA, et al. Innate lymphoid cells promote lung tissue homeostasis following acute influenza virus infection. *Nat Immunol* (2011) 12:1045–54. doi: 10.1031/ni.2131
- Britanova L, Dieffenbach A. Interplay of innate lymphoid cells and the microbiota. *Immunol Rev* (2017) 279:36–51. doi: 10.1111/imr.12580
- Mortha A, Burrows K. Cytokine networks between innate lymphoid cells and myeloid cells. *Front Immunol* (2018) 9:191. doi: 10.3389/fimmu.2018.00191
- Golebski K, Ros XR, Nagasawa M, van Tol S, Heesters BA, Aglmous H, et al. IL-1 $\beta$ , IL-23, and TGF- $\beta$  drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation. *Nat Commun* (2019) 10:2162. doi: 10.1038/s41467-019-09883-7
- Artis D, Spits H. The biology of innate lymphoid cells. *Nature* (2015) 517:293–301. doi: 10.1038/nature14189
- Sciumè G, Shih H-Y, Mikami Y, O'Shea JJ. Epigenomic views of innate lymphoid cells. *Front Immunol* (2017) 8:1579. doi: 10.3389/fimmu.2017.01579
- Vivier E, Artis D, Colonna M, Dieffenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on. *Cell* (2018) 174:1054–66. doi: 10.1016/j.cell.2018.07.017
- Silverstein NJ, Wang Y, Manickas-Hill Z, Carbone C, Dauphin A, Boribong BP, et al. Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection. *eLife* (2022) 11:e74681. doi: 10.7554/eLife.74681
- Cooper RJ, Hallett R, Tullo AB, Klapper PE. The epidemiology of adenovirus infections in greater Manchester, UK 1982–96. *Epidemiol Infect* (2000) 125:333–45. doi: 10.1017/S0950268899004550

13. D'Ambrosio E, Del Grosso N, Chicca A, Midulla M. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. *J Hyg (Lond)* (1982) 89:155–61. doi: 10.1017/S0022172400070650
14. Evans AS. Latent adenovirus infections of the human respiratory tract. *Am J Hyg* (1958) 67:256–66. doi: 10.1093/oxfordjournals.aje.a119932
15. Garnett CT, Talekar G, Mahr JA, Huang W, Zhang Y, Ornelles DA, et al. Latent species c adenoviruses in human tonsil tissues. *J Virol* (2009) 83:2417–28. doi: 10.1128/JVI.02392-08
16. Leung AY-H, Chan M, Cheng VC-C, Yuen K-Y, Kwong Y-L. Quantification of adenovirus in the lower respiratory tract of patients without clinical adenovirus-related respiratory disease. *Clin Infect Dis* (2005) 40:1541–4. doi: 10.1086/429627
17. Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance. *Eur J Microbiol Immunol (Bp)* (2014) 4:26–33. doi: 10.1556/EuJMI.4.2014.1.2
18. Mennechet FJD, Paris O, Ouoba AR, Salazar Arenas S, Sirima SB, Takoudjou Dzomo GR, et al. A review of 65 years of human adenovirus seroprevalence. *Expert Rev Vaccines* (2019) 18:597–613. doi: 10.1080/14760584.2019.1588113
19. Scott MK, Chommanard C, Lu X, Appelgate D, Grenz L, Schneider E, et al. Human adenovirus associated with severe respiratory infection, Oregon, USA, 2013–2014. *Emerg Infect Dis* (2016) 22:1044–51. doi: 10.3201/eid2206.151898
20. Capasso C, Garofalo M, Hirvonen M, Cerullo V. The evolution of adenoviral vectors through genetic and chemical surface modifications. *Viruses* (2014) 6:832–55. doi: 10.3390/v6020832
21. Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. *Hum Vaccin Immunother* (2016) 12:2064–74. doi: 10.1080/21645515.2016.1165908
22. Jönsson F, Kreppel F. Barriers to systemic application of virus-based vectors in gene therapy: Lessons from adenovirus type 5. *Virus Genes* (2017) 53:692–9. doi: 10.1007/s11262-017-1498-z
23. Kumar RK, Foster PS, Rosenberg HF. Respiratory viral infection, epithelial cytokines, and innate lymphoid cells in asthma exacerbations. *J Leukoc Biol* (2014) 96:391–6. doi: 10.1189/jlb.3RI0314-129R
24. Gregory SM, Nazir SA, Metcalf JP. Implications of the innate immune response to adenovirus and adenoviral vectors. *Future Virol* (2011) 6:357–74. doi: 10.2217/fvl.11.6
25. Tran TTP, Tran TH, Kremer EJ. IgG-complexed adenoviruses induce human plasmacytoid dendritic cell activation and apoptosis. *Viruses* (2021) 13:1699. doi: 10.3390/v13091699
26. Chéneau C, Eichholz K, Tran TH, Tran TTP, Paris O, Henriquet C, et al. Lactoferrin retargets human adenoviruses to TLR4 to induce an abortive NLRP3-associated pyroptotic response in human phagocytes. *Front Immunol* (2021) 12:685218. doi: 10.3389/fimmu.2021.685218
27. Eichholz K, Tran TH, Chéneau C, Tran TTP, Paris O, Pugniere M, et al. Adenovirus- $\alpha$ -Defensin complexes induce NLRP3-associated maturation of human phagocytes via toll-like receptor 4 engagement. *J Virol* (2022) 96:e01850–21. doi: 10.1128/jvi.01850-21
28. Chéneau C, Kremer EJ. Adenovirus–extracellular protein interactions and their impact on innate immune responses by human mononuclear phagocytes. *Viruses* (2020) 12:1351. doi: 10.3390/v12121351
29. Lopez-Lastra S, Masse-Ranson G, Fiquet O, Darche S, Serafini N, Li Y, et al. A functional DC cross talk promotes human ILC homeostasis in humanized mice. *Blood Adv* (2017) 1:601–14. doi: 10.1182/bloodadvances.2017004358
30. Roy S, Jaeson MI, Li Z, Mahboob S, Jackson RJ, Grubor-Bauk B, et al. Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes. *Vaccine* (2019) 37:1266–76. doi: 10.1016/j.vaccine.2019.01.045
31. Parronchi P, Carli MD, Manetti R, Simonelli C, Sampognaro S, Piccinini MP, et al. IL-4 and IFN ( $\alpha$  and  $\gamma$ ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. *J Immunol* (1992) 149:2977–83.
32. Weaver EA, Barry MA. Low seroprevalent species d adenovirus vectors as influenza vaccines. *PLoS One* (2013) 8:e73313. doi: 10.1371/journal.pone.0073313
33. Smith JG, Nemerow GR. Mechanism of adenovirus neutralization by human  $\alpha$ -defensins. *Cell Host Microbe* (2008) 3:11–9. doi: 10.1016/j.chom.2007.12.001
34. Eichholz K, Bru T, Tran TTP, Fernandes P, Welles H, Mennechet FJD, et al. Immune-complexed adenovirus induce AIM2-mediated pyroptosis in human dendritic cells. *PLoS Pathog* (2016) 12:e1005871. doi: 10.1371/journal.ppat.1005871
35. Kremer EJ, Boutin S, Chillon M, Danos O. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. *J Virol* (2000) 74:505–12. doi: 10.1128/JVI.74.1.505-512.2000
36. Valdez Y, Kyei SK, Poon GFT, Kokaji A, Woodside SM, Eaves AC, et al. Efficient enrichment of functional ILC subsets from human PBMC by immunomagnetic selection. *J Immunol* (2018) 200:51.13–3. Immunology 2018™ Meeting Abstracts
37. Kolegraf K, Nava P, Laur O, Parkos CA, Nusrat A. Characterization of full-length and proteolytic cleavage fragments of desmoglein-2 in native human colon and colonic epithelial cell lines. *Cell Adh Migr* (2011) 5:306–14. doi: 10.4161/cam.5.4.16911
38. Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. *J Virol* (2005) 79:14595–605. doi: 10.1128/JVI.79.23.14595-14605.2005
39. Tran TTP, Eichholz K, Amelio P, Moyer C, Nemerow GR, Perreau M, et al. Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells. *PLoS Pathog* (2018) 14:e1007127. doi: 10.1371/journal.ppat.1007127
40. Loustalot F, Kremer EJ, Salinas S. Membrane dynamics and signaling of the coxsackievirus and adenovirus receptor. *Int Rev Cell Mol Biol* (2016) 322:331–62. doi: 10.1016/bs.ircmb.2015.10.006
41. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for coxsackie b viruses and adenoviruses 2 and 5. *Science* (1997) 275:1320–3. doi: 10.1126/science.275.5304.1320
42. Ercolano G, Wyss T, Salomé B, Romero P, Trabaneli S, Jandus C. Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells. *J Leukoc Biol* (2020) 108:723–37. doi: 10.1002/JLB.5MA0120-209R
43. Mazzurana L, Czarnewski P, Jonsson V, Wigge L, Ringnér M, Williams TC, et al. Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid cells revealed by full-length single-cell RNA-sequencing. *Cell Res* (2021) 31:554–68. doi: 10.1038/s41422-020-00445-x
44. Maguire CA, Sapinoro R, Girgis N, Rodriguez-Colon SM, Ramirez SH, Williams J, et al. Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and  $\alpha$ v $\beta$ 3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens. *Vaccine* (2006) 24:671–82. doi: 10.1016/j.vaccine.2005.08.038
45. Adams WC, Bond E, Havenga MJE, Holterman L, Goudsmit J, Karlsson Hedestam GB, et al. Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. *J Gen Virol* (2009) 90:1600–10. doi: 10.1099/vir.0008342-0
46. Korokhov N, de Grujil TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, et al. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. *Cancer Biol Ther* (2005) 4:289–94. doi: 10.4161/cbt.4.3.1499
47. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I  $\alpha$ 2 domain at the surface of human epithelial and b lymphoblastoid cells. *EMBO J* (1997) 16:2294–306. doi: 10.1093/emboj/16.9.2294
48. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group b adenoviruses. *Nat Med* (2003) 9:1408–12. doi: 10.1038/nm952
49. Koizumi N, Mizuguchi H, Kondoh M, Fujii M, Hayakawa T, Watanabe Y. Efficient gene transfer into human trophoblast cells with adenovirus vector containing chimeric type 5 and 35 fiber protein. *Biol Pharm Bull* (2004) 27:2046–8. doi: 10.1248/bpb.27.2046
50. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting: Adenovirus receptors. *Rev Med Virol* (2009) 19:165–78. doi: 10.1002/rmv.612
51. Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, et al. Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. *J Virol* (2011) 85:6390–402. doi: 10.1128/JVI.00514-11
52. Coughlan L, Kremer EJ, Shayakhmetov DM. Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens. *Mol Ther* (2022) 30: S152500162200034X. doi: 10.1016/j.ymthe.2022.01.034
53. Bu W, Joyce MG, Nguyen H, Banh DV, Aguilar F, Tariq Z, et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in b cells and epithelial cells. *Immunity* (2019) 50:1305–1316.e6. doi: 10.1016/j.immuni.2019.03.010
54. Snijder J, Ortego MS, Weidle C, Stuart AB, Gray MD, McElrath MJ, et al. An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus. *Immunity* (2018) 48:799–811.e9. doi: 10.1016/j.immuni.2018.03.026
55. Nimmerjahn F, Ravetch JV. Fc $\gamma$  receptors as regulators of immune responses. *Nat Rev Immunol* (2008) 8:34–47. doi: 10.1038/nri2206
56. Williams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of fc $\gamma$  receptors in dendritic cells and macrophages. *Nat Rev Immunol* (2014) 14:94–108. doi: 10.1038/nri3582
57. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. *J Exp Med* (2008) 205:2717–25. doi: 10.1084/jem.20081786



58. Ouoba AR, Paris O, Adawaye C, Dzomo GT, Fouda AA, Kania D, et al. Prevalence of neutralizing antibodies against adenoviruses types -C5, -D26 and -B35 used in vaccination platforms, in healthy and HIV-infected adults and children from Burkina Faso and Chad. *medRxiv* (2022). doi: 10.1101/2022.06.07.2227607
59. Bartemes KR, Kephart GM, Fox SJ, Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. *J Allergy Clin Immunol* (2014) 134:671–678.e4. doi: 10.1016/j.jaci.2014.06.024
60. Ohne Y, Silver JS, Thompson-Snipes L, Collet MA, Blanck JP, Cantarel BL, et al. IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. *Nat Immunol* (2016) 17:646–55. doi: 10.1038/ni.3447
61. Sheikh A, Abraham N. Interleukin-7 receptor alpha in innate lymphoid cells: More than a marker. *Front Immunol* (2019) 10:2897. doi: 10.3389/fimmu.2019.02897
62. Surace L, Doisne J-M, Croft CA, Thaller A, Escoll P, Marie S, et al. Dichotomous metabolic networks govern human ILC2 proliferation and function. *Nat Immunol* (2021) 22:1367–74. doi: 10.1038/s41590-021-01043-8
63. Kotas ME, Locksley RM. Why innate lymphoid cells? *Immunity* (2018) 48:1081–90. doi: 10.1016/j.immuni.2018.06.002
64. Fan X, Rudensky AY. Hallmarks of tissue-resident lymphocytes. *Cell* (2016) 164:1198–211. doi: 10.1016/j.cell.2016.02.048
65. King CR, Zhang A, Mymryk JS. The persistent mystery of adenovirus persistence. *Trends Microbiol* (2016) 24:323–4. doi: 10.1016/j.tim.2016.02.007
66. Martinez-Gonzalez I, Mathä L, Steer CA, Ghaedi M, Poon GFT, Takei F. Allergen-experienced group 2 innate lymphoid cells acquire memory-like properties and enhance allergic lung inflammation. *Immunity* (2016) 45:198–208. doi: 10.1016/j.immuni.2016.06.017
67. Tanaka T, Narazaki M, Masuda K, Kishimoto T. Regulation of IL-6 in immunity and diseases. *Adv Exp Med Biol* (2016) 941:79–88. doi: 10.1007/978-94-024-0921-5\_4
68. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. *Eur J Immunol* (2010) 40:1830–5. doi: 10.1002/eji.201040391
69. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. *Science* (2009) 324:1569–72. doi: 10.1126/science.1174182
70. Parmigiani A, Pallin MF, Schmidtmayerova H, Lichtenheld MG, Pahwa S. Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells. *Hum Immunol* (2011) 72:115–23. doi: 10.1016/j.humimm.2010.10.015
71. Lim AI, Di Santo JP. ILC-poiesis: Ensuring tissue ILC differentiation at the right place and time. *Eur J Immunol* (2019) 49:11–8. doi: 10.1002/eji.201747294
72. Yang J, Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. *Mol Ther* (2004) 9:846–55. doi: 10.1016/j.yth.2004.01.010
73. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. *Cytokine Growth Factor Rev* (2011) 22:121–30. doi: 10.1016/j.cytogfr.2011.06.001
74. Pandya JM, Lundell A-C, Andersson K, Nordström I, Theander E, Rudin A. Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. *Arthritis Res Ther* (2017) 19:20. doi: 10.1186/s13075-017-1224-1
75. Spurrell JCL, Wiehler S, Zaheer RS, Sanders SP, Proud D. Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. *Am J Physiol Lung Cell Mol Physiol* (2005) 289:L85–95. doi: 10.1152/ajplung.00397.2004
76. Hayney MS, Henriquez KM, Barnett JH, Ewers T, Champion HM, Flannery S, et al. Serum IFN- $\gamma$ -induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults. *J Clin Virol* (2017) 90:32–7. doi: 10.1016/j.jcv.2017.03.003